Traffic:
10E
10W
15N
15S
57N
57S
60E
60W
210E
210W
This Site
Web Search
powered by
YAHOO! SEARCH
Subscriber Services
|
Home Delivery
|
e-Edition
|
Alerts
|
RSS
Home
News
Ontario
Rancho Cucamonga
Pomona
Upland
Claremont
Montclair
Chino Valley
California
Crime & Public Safety
Elections
Education
S.B. County Watch
Upland Watch
I.E.: Medicare Testing Ground
Sports
Buy Event Tickets Now
Golf - Tee Times and Courses
Preps
Reign Hockey
Rancho Cucamonga Quakes
Local Colleges
USC
UCLA
Lakers
Clippers
Dodgers
Angels
Ducks
Soccer
Motor Sports
Horse Racing
Live Odds
Business
Autos
Real Estate News
Technology
Opinions
Editorial
Letters
Columnists
Blogs
LA.COM
Buy Tickets
Movies
TV
Music
Shopping & Beauty
Recreation
Neighborhood
Arts
Living
Dining
Find A Restaurant
Lottery
Horoscopes
Travel
Trevor's Travels
Health
Crossword Puzzle
Local Casinos
Foothills Magazine
Info
Subscribe For Home Delivery
Contact Us
RSS
Podcast
Subscriber Services
Place An Ad
NIE
Classified
Place an Ad
Homes
Jobs
Auto
Search autos
Buy/Sell a car
Research/Financing a car
Find a dealer
Shopping
This week's ads
Obits
Directories
Local Business
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Elicio Therapeutics Inc.
Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
August 13, 2024
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Tickers
ELTX
Elicio Therapeutics Announces Closing of Private Placement of $20.0 Million Convertible Note
August 12, 2024
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Tickers
ELTX
Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public Offering
June 28, 2024
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Tickers
ELTX
Elicio Therapeutics Announces Proposed Public Offering
June 27, 2024
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Tickers
ELTX
Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P
June 27, 2024
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Tickers
ELTX
Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 05, 2024
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Tickers
ELTX
Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors
January 25, 2024
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Tickers
ELTX
Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium
January 17, 2024
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Tickers
ELTX
Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology Conference
January 16, 2024
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Tickers
ELTX
Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study
January 11, 2024
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Tickers
ELTX
Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic’s AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002
January 09, 2024
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Tickers
ELTX
Elicio Therapeutics Announces $7.0 Million Private Placement Financing
December 22, 2023
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Tickers
ELTX
Elicio Therapeutics to Present at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
December 04, 2023
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Tickers
ELTX
Elicio Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
November 09, 2023
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Tickers
ELTX
Elicio Therapeutics Presents Updated Preliminary Immunogenicity Data from the Ongoing Phase 1 Study of ELI-002 and New Preclinical Data on ELI-007 and ELI-008 at the Society for Immunotherapy of Cancer (SITC 2023) Annual Meeting
November 03, 2023
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Tickers
ELTX
Elicio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC 2023) Annual Meeting
October 11, 2023
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Tickers
ELTX
Elicio Therapeutics Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of ELI-002 at AACR Special Conference: Pancreatic Cancer
September 27, 2023
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Tickers
ELTX
Elicio Therapeutics Receives $2.6 Million Grant from the Gastro-Intestinal (GI) Research Foundation to Fund Research for Two Therapeutic Cancer Vaccines
September 07, 2023
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Tickers
ELTX
Elicio Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Tickers
ELTX
Elicio Therapeutics to Present Phase 1 Data on Cancer Vaccine Candidate, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancers at the AACR Special Conference on Pancreatic Cancer
September 05, 2023
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Tickers
ELTX
Elicio Therapeutics Announces Appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of Biometrics
August 28, 2023
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Tickers
ELTX
Elicio Therapeutics Reports Inducement Grants
August 22, 2023
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Tickers
ELTX
Elicio Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Updates
August 11, 2023
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Tickers
ELTX
Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating AMP-CpG Adjuvant Can Induce Potent and Durable Immune Response in Epstein-Barr Virus (EBV) Infectious Disease Model
August 09, 2023
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Tickers
ELTX
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Privacy Policy
|
Terms of Use
|
MNG Corporate Site Map
|
Copyright